Rajiv Raja
Executive Director, Oncology Translational Medicine GSK
Rajiv Raja is Executive Director, Clinical Biomarkers & Correlative Sciences within Oncology Translational Medicine at GSK, where he leads biomarker strategy across oncology clinical development programmes.
He previously held senior translational leadership roles at AstraZeneca and Genentech, focusing on immuno-oncology, clinical assay strategy and biomarker development. Rajiv holds a PhD in Molecular Genetics and Genomics from Oklahoma State University and brings over two decades of experience in translational oncology and clinical biomarker innovation.
Seminars
Wednesday 22nd July 2026
Panel Discussion: Leveraging Methylation-Based Liquid Biopsies to Deliver Earlier, More Actionable Trial Signals
9:30 am
- Where can methylation-based liquid biopsy create tangible impact in drug development today?
- Can methylation enable earlier and more confident clinical trial decision-making?
- What must happen for methylation to become embedded in mainstream clinical trial design?
Moderated by:
Tuesday 21st July 2026
Panel Discussion: From Signal to Strategy: How Liquid Biopsy is Rewriting Drug Development Decisions
1:00 pm
- Turning ctDNA and MRD signals into faster, higher confidence go/no-go decisions across modalities
- Cutting years and cost from development by replacing slow endpoints with early molecular insight
- Making liquid biopsy work in the real world: global logistics, scalability, and ROI for sponsors
